Autologous peripheral blood progenitor cell transplantation with <2 x 10(6) CD34(+)/kg: an analysis of variables concerning mobilisation and engraftment

Hematol J. 2000;1(6):374-81. doi: 10.1038/sj/thj/6200057.

Abstract

Introduction: This study analyses the factors affecting mobilisation and engraftment in autologous peripheral blood progenitor cell transplantation according to the number of CD34(+) re-infused.

Materials and methods: A total of 190 patients underwent mobilisation with G-CSF alone (n=113) or in combination with chemotherapy (n=77). A total of 116 patients (61%) were autografted with <2 x 10(6) CD34(+) cells/kg and 74 patients were transplanted with >2 x 10(6) CD34(+) cells/kg. Rates of granulocyte and platelet recovery were estimated using the product-limit method of Kaplan-Meier and compared using a log-rank test. The Cox regression model was used for the multivariate analysis of factors influencing engraftment. Differences between cohorts were evaluated by one-way ANOVA or Mann-Whitney tests, and multivariate analysis was performed using a stepwise lineal regression.

Results: Neutrophil and platelet engraftment was significantly longer with <2 x 10(6)/CD34(+)/kg (12 vs 10 days, P=0.014 and 16 vs 13 days, P=0.0001 respectively). Platelet recovery was affected by exposure to alkylating agents (P=0.04), refractory disease (P=0.02) and AML (P=0.0001), but only the last two variables remained significant in Cox regression (P<0.01). Granulocyte engraftment was longer in CML (univariate, P=0.04) and in refractory disease (multivariate, P=0.02). In patients re-infused with >2 x 10(6)/CD34(+)/kg, the Cox model did not identify prognostic factors for haematopoietic recovery.

Conclusion: Although mobilisation schedules and disease status influenced not only the yield of progenitor cells, but also the engraftment kinetics, the number of CD34(+) re-infused was the main predictor of haematopoietic recovery. While engraftment succeeded in most of the cases, the re-infusion of >2 x 10(6)/CD34(+)/kg resulted in significantly shorter recovery times.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antigens, CD34 / analysis
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Blood Cell Count
  • Caspase 14
  • Caspases / administration & dosage
  • Cerebral Hemorrhage / etiology
  • Cohort Studies
  • Combined Modality Therapy
  • Cyclophosphamide / administration & dosage
  • Cytarabine / administration & dosage
  • Erythropoietin / pharmacology
  • Etoposide / administration & dosage
  • Female
  • Graft Survival
  • Granulocyte Colony-Stimulating Factor / pharmacology
  • Hematologic Neoplasms / drug therapy
  • Hematologic Neoplasms / therapy*
  • Hematopoietic Stem Cell Mobilization / methods*
  • Hematopoietic Stem Cell Transplantation / adverse effects
  • Hematopoietic Stem Cell Transplantation / methods*
  • Hematopoietic Stem Cell Transplantation / statistics & numerical data
  • Humans
  • Hydroxyurea / administration & dosage
  • Infections / etiology
  • Infections / mortality
  • Leukapheresis / methods
  • Life Tables
  • Male
  • Middle Aged
  • Neoplasms / therapy
  • Proportional Hazards Models
  • Transplantation Conditioning / adverse effects
  • Transplantation Conditioning / methods
  • Transplantation Conditioning / mortality
  • Transplantation, Autologous

Substances

  • Antigens, CD34
  • Cytarabine
  • Erythropoietin
  • Granulocyte Colony-Stimulating Factor
  • Etoposide
  • Cyclophosphamide
  • CASP14 protein, human
  • Caspase 14
  • Caspases
  • Hydroxyurea